Key points are not available for this paper at this time.
IgA Nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been advances made in the understanding of IgAN pathophysiology and new therapeutic options have emerged. We now have the first FDA- and EMA-approved therapies for IgAN, with many more novel agents in advanced trials. These unprecedented developments reinforce the need to improve individual disease risk stratification and expand and refine the criteria to choose the best treatment for each patient.
Sáez-Rodríguez et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: